A detailed history of Kingdon Capital Management, L.L.C. transactions in Immuno Gen, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 200,000 shares of IMGN stock, worth $0. This represents 0.07% of its overall portfolio holdings.

Number of Shares
200,000
Holding current value
$0
% of portfolio
0.07%

Shares

0 transactions
Quarter Operation Price Per share shares change shares Held SEC Form

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Kingdon Capital Management, L.L.C. Portfolio

Follow Kingdon Capital Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.